IL-17 appears to be mainly involved in AD-related pathology, as its presence is associated with exacerbated cognitive decline and synaptic dysfunction [46], while blocking IL-17 has been shown to reduce Aβ pathology [47]. The gene discussed is IL17A; the disease is Mental deterioration.